-
Alexion Pharmaceuticals (ALXN) CFO Successor Is A Strong Replacement - RBC
-
Alexion to Present at the RBC Capital Markets Annual Healthcare Conference
-
Alexion Pharmaceuticals (ALXN) PT Raised to 'Street High' $186 at RBC Capital
-
Alexion Pharmaceuticals (ALXN) PT Lowered to $165 at RBC Capital
-
Alexion Pharma (ALXN): Patent Ruling an Incremental Negative, But Competition Years Away - RBC
-
Alexion Pharma (ALXN) Could Consider Buying Ra Pharmaceuticals (RARX) Outright - RBC
-
Alexion (ALXN): '1210 Patent Challenge Looks Like a Troll - RBC
-
Alexion Pharmaceuticals (ALXN) PT Raised to $170 at RBC Capital
-
Vertex Pharma (VRTX), Alexion Pharma (ALXN) Least Impacted from Trump Drug Policies - RBC
-
Alexion Pharmaceuticals (ALXN) Defended at RBC
-
RBC Sees 10-15% Move in Alexion Pharma (ALXN) Following ALXN-1210 Results
-
Alexion Pharmaceuticals (ALXN) PT Raised to $166 at RBC Capital
-
RBC Capital Starts Alexion Pharmaceuticals (ALXN) at Outperform
-
RBC Capital Reiterates Outperform Rating and $177 PT on Alexion Pharma (ALXN) Following New CEO Announcement
-
Alexion Pharmaceuticals (ALXN) PT Lowered to $177 at RBC Capital Following PNH Update
-
Alexion Pharma (ALXN): Worst Case Scenario Averted - RBC
-
Alexion Pharma (ALXN): Soliris In DGF Was A Rounding Error - RBC
-
Alexion (ALXN): Soliris Core Business Alone is Worth $115/Share - RBC
-
Notable Analyst Rating Changes 9/15: (GPN) (AKRX) (EXTR) Upgraded; (VFC) (FGP) (ATRA) Downgraded
-
U.S. biotech stocks win back investors in big July run
-
UPDATE: RBC Capital Starts Alexion Pharmaceuticals (ALXN) at Outperform
-
Notable Analyst Rating Changes 6/27: (GOLD) (GME) (ALXN) Upgraded; (RMD) (PCAR) (LYB) Downgraded
-
Dyax Corp (DYAX) Gains on Takeover Speculation
-
Notable Analyst Rating Changes 02/20: (RDN) (AFL) (ALXN) Upgraded; (BCS) (SAI) (WIN) Downgraded
-
David Moenning's Daily State of the Markets: 4/23